April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).
When implanted with Biotronik's Plexa ProMRI S DX lead, the hybrid ICD Acticor systems offer dual-chamber diagnostics without the need for an atrial lead. Importantly, all three Acticor DX devices feature a new DF4 header configuration with a penta-polar electrode lead cable design that simplifies the implant procedure for physicians.
Larry Chinitz, M.D., and Lior Jankelson, M.D., Ph.D., New York, N.Y.; and Chafik Assal, M.D., Charleston, W.Va.; are among the first in the country to treat patients with Acticor.
"Smaller device systems with greater diagnostic capabilities and longer battery life improve how we treat patients," said George Thomas, M.D., New York, N.Y. "The new Acticor DX devices offer a simplified DF4 lead connection for the DX system. In my first cases, the slimmer, smoother device fit more easily in the pocket and substantially improved patient comfort post-op. These features bring clinical value and enhance patient quality of life."
Biotronik's unique DX technology enables the detection of silent atrial fibrillation; this helps prevent stroke, enhances diagnostic accuracy to improve clinical decision-making and allows for supraventricular tachycardia (SVT) discrimination to prevent unnecessary shocks. By reducing the number of leads, procedure times are faster and costs and complications are decreased.
The U.S. Food and Drug Administration (FDA) approved Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX in March, along with the Rivacor device family for the treatment of tachycardia and heart failure. Acticor and Rivacor are the smallest and slimmest cardiac rhythm management (CRM) devices approved for use in full-body, 3 Tesla (3T) magnetic resonance imaging (MRI) scans, according to the company. The new devices measure just 10 mm thin, with a smooth, rounded BIOshape that eases implantation and increases patient comfort. The devices have improved battery longevity — nearly 15 years for Rivacor VR-T, 13.5 years for Rivacor DR-T, 14 years for Acticor DX, and 11 years for both Rivacor CRT and Acticor CRT-DX. They are backed by extended device warranties.
Read the article "FDA Approves 3T Acticor and Rivacor Tachycardia Devices from Biotronik"
The ultraslim Acticor and Rivacor device systems feature MRI AutoDetect, Closed Loop Stimulation and Biotroink Home Monitoring. As a result, they provide more efficient MRI access, individualized physiological rate response and remote monitoring that is proven to reduce all-cause mortality in heart failure patients by more than 60 percent
For more information: www.biotronik.com